News

EMA Issues Positive Opinion for Itvisma (Onasemnogene Abeparvovec) Gene Therapy for Spinal Muscular Atrophy

EMA · Spinal Muscular Atrophy (SMA) · 3 min

EMA Issues Positive Opinion for Cenrifki (Tolebrutinib) Multiple Sclerosis Treatment

EMA · 2 min

EMA Recommends First RNA-Based Veterinary Vaccine Nobivac NXT HCPChFeLV for Cats

EMA · 2 min

EMA Recommends Approval of Plozasiran (Redemplo) for Rare Triglyceride Disorder FCS

EMA · 2 min

EMA CHMP Recommends Five New Medicines Including Tolebrutinib (Cenrifki) for Approval in April 2026

EMA · 2 min

Aetna Standardizes 88% of Prior Authorization Volume, Exceeds Industry Commitments for Healthcare Access

2 min

Guerbet's Lipiodol Ultra Fluid Achieves EU Regulatory Milestone for Vascular Embolization Procedures

2 min

RNA Therapy Clinical Trials Market Reaches $3.4 Billion as Personalized Medicine Drives Growth Through 2035

2 min

Oncotelic Therapeutics Updates Partnership Strategy for Cancer Drug Development Pipeline

2 min

CLINUVEL Receives EMA Approval for SCENESSE Phase III Vitiligo Trial Starting 2026

EMA · 2 min

RenovoRx TAMP Therapy Platform Data Accepted for 2026 ASCO Presentation - Phase III TIGeR-PaC Trial Results

2 min

Genomics Services Market to Reach $24 Billion by 2033 as Precision Medicine Adoption Accelerates

2 min